SB-3CT alone substantially extended the overall survival time (median survival 31 vs 19 days; p < 0.01, log-rank test) of B16F10 tumor-bearing mice, and combined with anti-PD-1, enhanced the survival benefit (median survival 48 vs 19 days; p < 0.001; Fig. 2e). Here, PDCD1 is linked to neoplasm.